Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Jul;50(1):119–121. doi: 10.1038/bjc.1984.147

In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions.

J F Rossi, R Bataille
PMCID: PMC1976933  PMID: 6743509

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R. Localized and indolent myeloma. Blood. 1980 Sep;56(3):521–525. [PubMed] [Google Scholar]
  2. Bataille R., Sany J. Clinical evaluation of myeloma osteoclastic bone lesions: II. Induced hypocalcemia test using salmon calcitonin. Metab Bone Dis Relat Res. 1982;4(1):39–42. doi: 10.1016/0221-8747(82)90007-8. [DOI] [PubMed] [Google Scholar]
  3. Delmas P. D., Charhon S., Chapuy M. C., Vignon E., Briancon D., Edouard C., Meunier P. J. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res. 1982;4(3):163–168. doi: 10.1016/0221-8747(82)90013-3. [DOI] [PubMed] [Google Scholar]
  4. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  5. Durie B. G., Salmon S. E., Mundy G. R. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol. 1981 Jan;47(1):21–30. doi: 10.1111/j.1365-2141.1981.tb02758.x. [DOI] [PubMed] [Google Scholar]
  6. Gailani S., McLimans W. F., Mundy G. R., Nussbaum A., Roholt O., Zeigel R. Controlled environment culture of bone marrow explants from human myeloma. Cancer Res. 1976 Apr;36(4):1299–1304. [PubMed] [Google Scholar]
  7. Mundy G. R., Luben R. A., Raisz L. G., Oppenheim J. J., Buell D. N. Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med. 1974 Apr 18;290(16):867–871. doi: 10.1056/NEJM197404182901601. [DOI] [PubMed] [Google Scholar]
  8. Mundy G. R., Raisz L. G., Cooper R. A., Schechter G. P., Salmon S. E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974 Nov 14;291(20):1041–1046. doi: 10.1056/NEJM197411142912001. [DOI] [PubMed] [Google Scholar]
  9. Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
  10. RAISZ L. G. BONE RESORPTION IN TISSUE CULTURE. FACTORS INFLUENCING THE RESPONSE TO PARATHYROID HORMONE. J Clin Invest. 1965 Jan;44:103–116. doi: 10.1172/JCI105117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Valentin-Opran A., Charhon S. A., Meunier P. J., Edouard C. M., Arlot M. E. Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982 Dec;52(4):601–610. doi: 10.1111/j.1365-2141.1982.tb03936.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES